APT(SH:688617) 智通财经网·2026-02-26 12:37Core Viewpoint - Huatai Medical (688617.SH) reported a revenue of 2.584 billion yuan for the year 2025, representing a year-on-year growth of 25.08%, and a net profit attributable to the parent company of 821 million yuan, with a year-on-year increase of 21.91% [1] Group 1: Financial Performance - The company achieved a revenue of 2.584 billion yuan in 2025, marking a 25.08% increase compared to the previous year [1] - The net profit attributable to the parent company reached 821 million yuan, reflecting a growth of 21.91% year-on-year [1] Group 2: Factors Influencing Performance - The main reasons impacting operational performance include the company's ongoing market expansion efforts and various promotional activities, leveraging advantages in R&D, technology, quality, market, and channels to enhance product coverage and hospital admission rates [1] - The company emphasizes cost control, focusing R&D and sales expenses on the market promotion, clinical validation, and iterative development of core products like PFA, optimizing expenditure structure and rhythm through refined operations and scaled operations to achieve synchronized growth in net profit and revenue [1]